| Speakers |
| Session 1 | ||||
Education Implementation in RM companies in JAPAN | Seiji HORI VC Cell Therapy, FIRM, DIRECTOR Chairman of Education Implementation Committee
| Educational Background Professional Experiences • 2021 Director, VC Cell Therapy Inc. CTO • 2014 Sub-Division Head, iPS portal Inc. • 2001 Lecturer, Graduate School for Biostudies, Kyoto University • 1999 Researcher, Osaka Bioscience Institute • 1995 Researcher, Ciba-Geigy Japan, Co. Ltd. (Currently, Novartis Pharma) • 1988 Researcher, Taiyo Fishery, Co. Ltd. (Currently Maruha-Nichiro)
Professional Organizations • 2023 Visiting Professor, Hiroshima University • 2022 Team Leader, Riken Batton Zone Program (Ophthalmologic Therapy) • 2019 Chair of Education Implementation Committee of FIRM Main Publications • Elife. 2024 May 9:12:RP92510. doi: 10.7554/eLife.92510. Pigmentation level of human iPSC-derived RPE does not indicate a specific gene expression profile Yoko Nakai-Futatsugi, Jianshi Jin, Taisaku Ogawa, Noriko Sakai , Akiko Maeda, Ken-Ichi Hironaka , Masakazu Fukuda , Hiroki Danno , Yuji Tanaka, Seiji Hori , Katsuyuki Shiroguchi , Masayo Takahashi | ||
| Current Status and Outlook of Cell Therapy in Taiwan | Yueh-Ping Liu Department of Medical Affairs Ministry of Health and Welfare of Taiwan, Director-General | Educational Background • 2014-2016 Graduated LLM, Law School, Ming Chuan University, Taipei, Taiwan(R.O.C.) • 1992-1999 Graduated MD, the Medical College of National Taiwan University, Taipei, Taiwan(R.O.C.) Professional Experiences • 2017-2020 Senior Special Technician, Department of Medical Affairs, Ministry of Health and Welfare, Taiwan (R.O.C.) • 2011-2014 Division Chief at Division of Medical Affairs, Department of health, Taipei City Government, Taiwan (R.O.C.) • 2005-Present Attending Physician at Department of Emergency Medicine, National Taiwan University Hospital, Taiwan (R.O.C.) Professional Organizations • 2021-Present Chief Executive Officer, Taiwan Organ Registry and Sharing Center • 2020-Present Member of the Board of Directors, Joint Commission of Taiwan • 2016-Present Commissioner of the medical review committee, Chia-Yi County government • 2010-Present Commissioner of Emergency Ultrasound Committee, Taiwan Society of Emergency Medicine • 2006-Present Medical consultant of Taipei City Fire Department • 2006-Present Commissioner of Pediatric Emergency Committee, Taiwan Society of Emergency Medicine | ||
| Challenges and Solutions in Global Regenerative Medicine HRD | Shih-Chia Lin Foundation of Medical Professionals Alliance in Taiwan Executive Director  | Educational Background • Institute of Health and Welfare Policy, National Yang Ming University • Department of Public Health, National Taiwan University
Professional Experiences • Foundation of Medical Professionals Alliance in Taiwan, Executive Director • TaiAn Technologies Corp., General Manager • Chairman of Taiwan-Korea Parliamentary Friendship Group (한국-대만 의원친선협회장) • Taiwan Bio Industry Organization, Board Member • Locus Cell Co., Ltd, CEO • Eighth Legislative Yuan, Member • Office of the Vice Premier of the Executive Yuan, Director • Taiwan Task Force for Medical Travel of the Ministry of Health and Welfare, Expert Consultant • Medical Excellence Taiwan (MET), Advisor Main Publications • “Prosperity and Health-Recommendations for Taiwan's Development of Innovative Biomedical Policies”- Chief Editor • “Future Medicine: Development and Trends in Regenerative Medicine”-Author | ||
| Session 2 | Session chair Dae-won Kim Yonsei University, Professor
| |||
| Landscape of Genome Editing Therapeutics | Seokjoong Kim GenEdit, Head of Platform
| Educational Background • 2001-2006 Ph.D. Department of Molecular Medicine, University of Texas Health Science Center at San Antonio • 1997-2001 B.E. Department of Biological Engineering, Handong University Professional Experiences • 2024-Present Head of Platform, GenEdit. • 2010-2022 Managing Director, ToolGen, Inc. • 2007-2010 Postdoctoral researcher, Department of Chemistry, Seoul National University Main Publications • Lee, J.-S., et al., Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice. Nucleic acids research, 2020. 48(1): p. 130-140. (Corresponding author) - Kim, Y., et al., A library of TAL effector nucleases spanning the human genome. Nature biotechnology, 2013. 31(3): p. 251-258. (Corresponding author) - Kim, S., et al., Preassembled zinc-finger arrays for rapid construction of ZFNs. Nature methods, 2011. 8(1): p. 7 - Kim, S., et al., Mediator is a transducer of Wnt/β-catenin signaling. Journal of Biological Chemistry, 2006. 281(20): p. 14066-14075. (366 citation)
Patents - 11 PCT patent family (>90 international patents) | ||
| Safer Viral Platforms for Long-Term Gene Therapy Effects | Gwang-il Im Sookmyung Women's University Professor
| Professional Experiences • Sookmyung Women's University, Department of Chemical and Biological Engineering (Department of Pharmaceutical Sciences), Professor | ||
| Revolutionizing Cancer Treatment: Challenges and Opportunities of CAR-T Cell Therapy | Yong Gu Lee College of Pharmacy, Hanyang University Assistant Professor  | Educational Background • 2018 Purdue University, West Lafayette, IN / Ph.D. Interdisciplinary Life Science program / Thesis Advisor: Dr. Philip S. Low • 2012 Georgetown University, Washington, DC / M.S. Tumor biology in Biomedical Science • 2011 Sunkyunkwan University, Seoul, Republic of Korea / B.S. College of Biotechnology and Bioengineering Professional Experiences • 2021-Present Hanyang University, College of Pharmacy - Assistant Professor • 2018-2021 University of Pennsylvania, School of Medicine, Center for Cellular Immunotherapies - Postdoctoral Research Fellow / Advisors: Dr. Carl H. June and Dr. Marco Ruella
Main Publications • Yong Gu Lee, Nicholas Yang, Inkook Chun, Patrizia Porazzi, Alberto Carturan, Luca Paruzzo, Christopher Tor Sauter, Puneeth Guruprasad, Raymone Pajarillo, Marco Ruella. Apoptosis: a Janus bifrons in T-cell immunotherapy. Journal for Immunotherapy of Cancer (2023). 11(4) • Yong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, Raymone Pajarillo, Christopher Tor Sauter, Ruchi Patel, Hatcher J Ballard, Seok Jae Hong, Inkook Chun, Nicholas Yang, Kimberly V. Amelsberg, Katherine D. Cummins, Jakub Svoboda, Saar Gill, Elise A. Chong, Khrystyna North, Sarah E. Church, Joseph A. Fraietta, Wan-Jung Chang, Simon F. Lacey, Xueqing Maggie Lu, Yunlin Zhang, Kanupriya Whig, David C. Schultz, Sara Cherry, James Gerson, Stephen J. Schuster, Patrizia Porazzi, and Marco Ruella. Cancer Discovery (2022). 12(10): 2372-2391 • Nathan Singh*, Yong Gu Lee*, Olga Shestova, Pranali Ravikumar, Katharina E hayer, Seok Jae Hong, Xueqing Maggie Lu, Raymone Pajarillo, Sangya Agarwal, Shunichiro Kuramitsu, Elena L. Berger, Ophir Shalem, Matthew D Weizman, Noelle V. Frey, Shannon L. Maude, Stephan A. Grupp, Carl H. June, Saar Gill and Marco Ruella. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. Cancer Discovery. April 1 2020 10 (4) 552-567; DOI:10.1158/2159-8290.CD-0813. Selected as cover page for the issue. *Co-first author. • Yong Gu Lee, Haiyan Chu, Yingjuan Lu, Christopher P. Leamon, Madduri Srinivasarao, Karson S. Putt and Philip S. Low, Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. Nature communications. 2019. 10(1): 2681. • Yong Gu Lee, Isaac Marks, Madduri Srinivasarao, Ananda Kandaluru, Mahalingam S., Haiyan Chu, and Philip S. Low. Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. Cancer research 79.2 (2019): 387-396. | ||
| Session 3 | Session chair Yang, Kisuk Incheon National University, Assistant professor
| |||
| Tissue-mimicking Biomaterials for Various Applications in Regenerative Medicine | Jung Seung Lee Sungkyunkwan University Assistant Professor
| Educational Background • 2011-2017 Ph.D., Department of Biotechnology, Yonsei University, Seoul, Korea • 2014-2011 B.S., Department of Biotechnology, Yonsei University, Seoul, Korea Professional Experiences • 2021-Present Adjunct Professor, Department of Biomedical Engineering, Sungkyunkwan University, Suwon, Korea • 2021-Present Assistant Professor, Department of IPHC, Sungkyunkwan University, Suwon, Korea • 2018-2021 Postdoctoral Associate, Koch Institute for Integrative Cancer Research, MIT, Cambridge, USA Main Publications • Lee JS et al,. A Multifunctional decellularized-gut suture platform, Matter 2023:6(7):2293-2311 • Lee JS et al,. Mechanically-reinforced and highly adhesive decellularized tissue-derived hydrogel for efficient tissue repair. Chem. Eng. J. 2022:427(1):130926 • Lee JS et al,. Tissue bead: Tissue-specific extracellular matrix microbeads to potentiate reprogrammed cell-based therapy. Adv. Funct. Mater. 2019:29(31):1807803 • Jin Y, Lee JS et al,. Three-dimensional brain-like microenvironments facilitate the direct reprogramming of fibroblasts into therapeutic neurons. Nat. Biomed. Eng. 2018:2:522-539 | ||
| Advanced Bioprinting Technology for Theragenerative Platform | Hyun-Do Jung Division of Materials Science and Engineering, Hanyang University Associate Professor
| Educational Background • 2008-2013 Ph.D. Materials Science and Engineering, Seoul National University, Seoul, Korea • 2004-2008 B.S. Materials Science and Engineering, Seoul National University, Seoul, Korea Professional Experiences • 2024-Present Associate Professor, Hanyang University, Seoul, Korea • 2014-2020 Senior/Principal Researcher, Research Institute of Advanced Manufacturing Technology, Korea Institute of Industrial Technology, Incheon, Korea • 2014-2014 Post-doctoral Researcher, Advanced Institute of Convergence Technology, Suwon, Korea • 2013-2014 Post-doctoral Researcher, Research Institute of Advanced Materials, Seoul, Korea
Professional Organizations • The Korean Society of Industrial and Engineering Chemistry, Committee Member of Division of Biomaterials • The Korean Tissue Engineering and Regenerative Medicine International Society (KTERMS), Committee member Main Publications • 3D-printed versatile biliary stents with nanoengineered surface for anti-hyperplasia and antibiofilm formation, Bioactive Materials 37, 172-190 • 3D-printed NIR-responsive bullets as multifunctional nanodrug platforms for image-guided local chemo-photothermal therapy, Chemical Engineering Journal 477, 147083 • 3D‐Printed Functional Hydrogel by DNA‐Induced Biomineralization for Accelerated Diabetic Wound Healing,. Advanced Science 10 (17), 2300816 • Topography‐Supported Nanoarchitectonics of Hybrid Scaffold for Systematically Modulated Bone Regeneration and Remodeling, Advanced Functional Materials 32 (51), 2206863 • Accelerated biodegradation of iron-based implants via tantalum-implanted surface nanostructures, Bioactive Materials 9, 239-250 | ||
| Employing Engineering Principles to Investigate Host-Microbiome Crosstalk | Woojung Shin Korea Advanced Institute of Science and Technology Assistant Professor  | Educational Background • 2016-2020 PhD, Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA • 2014-2015 MS, Department of Chemical Engineering, Sungkyunkwan University, Suwon, Korea • 2010-2014 BS, Department of Chemical Engineering, Sungkyunkwan University, Suwon, Korea Professional Experiences • 2023-Present Assistant Professor, Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea • 2021-2023 Postdoctoral Fellow, Wyss Institute for Biologically Inspired Engineering, Harvard Medical School, Boston, MA, USA & Massachusetts Institute of Technology (co-affiliation), Cambridge, MA, USA • 2020-2021 Postdoctoral Fellow, Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA Main Publications • Shin et al., Nature Reviews Bioengineering, 2024 • Shin and Kim, Nature Protocols, 2022 • Shin et al., iScience, 2022 • Shin et al., iScience, 2020 • Shin and Kim, PNAS, 2018 | ||
| Session 4 | Session chair Kim Dae-sung Korea Univerity Department of Biotechnology, Professor  | |||
| Development of embryonic stem Cells-derived cell therapeutics for Parkinsons disease treatment | Myung Soo Cho S.Biomedics Co., Ltd. Director of Research  | Educational Background • 1994-2001 M.S. & Ph.D., Department of Biological Science, College of Natural Science, Ajou University • 1988-1994 B.S., Department of Biological Science, College of Natural Science, Ajou University Professional Experiences • 2017-Present Director/Head of Research, R&D center, S.Biomedics Co., Ltd. • 2003-2017 Chief Researcher, R&D center, Jeil Pharm. Co., Ltd. • 2002-2003 Senior Researcher, IRMP, Medical Research Center, Seoul National University • 2001-2002 Senior Researcher, Duplogen Co., Ltd. • 2001-2002 Research instructor, Department of Microbiology. College of medicine, Ajou University
Main Publications • Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson’s disease. Cell Stem Cell 2024, 31:25-38 • Generation of retinal pigment epithelial cells from human embryonic stem cell-derived spherical neural masses. Stem Cell Res. 2012, 9(2):101-9. • Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale. Nature Protocols 2008, 3(12):1888-94. | ||
| Development of stem cell and extracellular vesicle therapies with high regenerative and immunomodulation capacities | Ssang-Goo Cho Konkuk University, Professor
| Educational Background • 1987-1998 BA/MS/Ph.D, Dept. of Genetic Engineering, Korea University, Seoul, Korea Professional Experiences • 2020-Present, CEO/CTO, StemExOne Ltd., Seoul Korea • 2020-2022, Dean, KU Institute of Technology, Konkuk University, Seoul, Korea • 2014-2016 Specialist, Medical & Pharm Sector, Korea Research Fund, Daejeon, Korea • 2012-Present, Director, Molecular & Cellular Reprogramming Center (MCRC), Konkuk University, Seoul, Korea • 2011-2012, visiting scientist, Institute Pasteur Korea, Gyeonggi-do, Korea • 2003-Present, Professor, Dept. of Stem Cell & Regenerative Biotech. (SCRB), Konkuk University, Seoul, Korea • 2001-2003, Research Professor, Life Sciences and Biotechnology, Korea University, Seoul, Korea • 2000-2001 Post-Doc., Mount Sinai School of Medicine, New York, USA • 1998-2000 Post-Doc., Creative Research Initiative (CRI) Center for Cell Death, Korea University, Seoul, Korea
• 2022-2023, President / Chair, Korean Society for Stem Cell Research (KSSCR) • 2022-2023 Borad Member, Regenerative Medicine Acceleration Foundation (RMAF), Seoul, Korea Main Publications • 205 SCI papers (many Top 5% journals) / 25 international patents/ 67 domestic patents/ 9 Tech transfers | ||
| Utilization of Human Induced Pluripotent Stem Cell-Derived Cell Models in New Drug Development | Dong-Hun Woo NEXEL Co., Ltd., Vice President  | Educational Background • 2007-2011 Ph.D. Korea University College of Life Sciences and Biotechnology, Seoul, Korea • 2005-2007 M.S.. Korea University College of Life Sciences and Biotechnology, Seoul, Korea • 1998-2004 B.S. Hanyang University College of Life Sciences, Seoul, Korea
Professional Experiences • 2013-Present COO/CTO, NEXEL Co., Ltd., Seoul, Korea • 2013-2016 Postdoc, College of Biomedical Sciences, University of Pennsylvania, PA, USA • 2011-2013 Postdoc, Lerner Research Institute, Cleveland Clinic, OH, USA
• Member, Korean Tissue Engineering and Regenerative Medicine • Member, HESI Cardiac Safety Committee, Stem Cell Working Group • Core Expert, Safety Evaluation Technologies, Ministry of Food and Drug Safety Main Publications • Modeling acute myocardial infarction and cardiac fibrosis using human induced pluripotent stem cell-derived multi-cellular heart organoids (Cell Death & Disease, 2024) • Enhancing a Wnt-Telomere Feedback Loop Restores Intestinal Stem Cell Function in a Human Organotypic Model of Dyskeratosis Congenita (Cell Stem Cell, 2016) • Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells (Cancer Cell. 2013) • Direct and indirect contribution of human embryonic stem cell-derived hepatocyte-like cells to liver repair in mice (Gastroenterology, 2012) | ||
